Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

@article{Koh2012SorafenibAM,
  title={Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.},
  author={Yoon Woo Koh and Manisha H Shah and Kitty Agarwal and Samantha K. McCarty and Bon Seok Koo and Victoria J Brendel and Chaojie Wang and Kyle Porter and David Jarjoura and Motoyasu Saji and Matthew D. Ringel},
  journal={Endocrine-related cancer},
  year={2012},
  volume={19 1},
  pages={
          29-38
        }
}
  • Y. KohM. Shah M. Ringel
  • Published 1 February 2012
  • Biology, Medicine, Chemistry
  • Endocrine-related cancer
Clinical trials using kinase inhibitors have demonstrated transient partial responses and disease control in patients with progressive medullary thyroid cancer (MTC). The goal of this study was to identify potential combinatorial strategies to improve on these results using sorafenib, a multikinase inhibitor with activity in MTC, as a base compound to explore signaling that might predict synergystic interactions. Two human MTC cell lines, TT and MZ-CRC-1, which harbor endogenous C634W or M918T… 

Figures and Tables from this paper

The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound

It is found that short-term sorafenib treatment could inhibit the downstream RAF effectors phosphorylated (p)-MEK and p-ERK in Bel7402 and SMMC7721 cells, while long-term SorafenIB treatment could induce a rebound of p-MEKand p- ERK expression in these two human HCC cell lines.

Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases

It appears that inhibition of only one receptor or molecule in a pathway is not as effective as simultaneous inhibition of different pathways, indicating the need to use combination therapy.

Sorafenib and Thyroid Cancer

The results suggest that sorafenib is a promising therapeutic option in patients with advanced thyroid cancer that is not responsive to traditional therapeutic strategies.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Investigation of the effects of RAF and MEK concurrent inhibition on tumor growth, migration, signaling and apoptosis induction in preclinical models of non-V600 BRAF mutant tumor cell lines suggests that combined blocking of RAFand MEK may achieve increased therapeutic response in non- V600 BRAf mutant tumors.

RET kinase inhibitors for RET-altered thyroid cancers

Although the approval of selpercatinib and pralsetinib in 2020 has profoundly benefited patients with RET-altered thyroid cancer, further research into optimal treatment strategies, mechanisms of drug resistance, long-term consequences of potent RET-inhibition, and development of more effective agents against emergent mutations are much needed.

State of the art and future directions in the systemic treatment of medullary thyroid cancer

The development of selective RET-inhibitors has expanded the therapeutic arsenal to control tumor growth in progressive MTC, with fewer adverse effects than multikinase inhibitors.

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Investigation of mTOR activity to RET-induced signaling and cell growth and whether growth suppression is enhanced by co-targeting RET and mTOR kinase activities establish mTOR as a key mediator of RET-mediated cell growth in thyroid cancer cells.

Novel treatment options for anaplastic thyroid cancer

New, affordable and individual genomic analysis combined with the opportunity to test these new treatments in primary cell cultures from every ATC patient in vitro, may permit the personalization of therapy, increasing the therapeutic effectiveness and avoiding the use of ineffectived drugs.

Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer

More research is needed to finally identify therapies able to control and to cure this disease and new molecules have been shown to be active against ATC.

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

Recent knowledge on RET resistance in NSCLC in pre-clinic and in clinical settings is explored and accordingly, the state-of-the-art in new drugs or combination of drugs development is explored.

References

SHOWING 1-10 OF 29 REFERENCES

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Sorafenib and sunitinib appear to be effective in patients with widely metastatic, progressive DTC, with most patients achieving SD or PR, despite having PD at baseline.

AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer

The data show that MAP/ERK kinase inhibition enhances the antitumor activity of sorafenib in vivo, supporting a rationale for multitargeted suppression of the angiogenesis and ERK signaling network in gastric cancer therapy.

BAY 43-9006 inhibition of oncogenic RET mutants.

BAY 43-9006 is a powerful inhibitor of the RET kinase and its potential as a therapeutic tool for RET-positive thyroid tumors, including those expressing V804 mutations merits study.

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

Evidence that both pathways converge on factors that regulate translation initiation and support therapeutic strategies in lung cancer that simultaneously suppress the RAS and AKT signaling network is provided.

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

The results provide the basis for a rational combination strategy against human EGFR WT gastric cancers, predicated on the understanding of cross-talk between the MEK and EGFR pathways.

Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.

These preclinical results support the inclusion of thyroid cancer patients in early-phase clinical trials combining RAS/RAF/MEK/ERK and PI-3K/AKT/mTOR pathway inhibition.

Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.

  • S. Sherman
  • Medicine, Biology
    The Journal of clinical endocrinology and metabolism
  • 2009
Treatment for patients with metastatic or advanced thyroid carcinoma now emphasizes clinical trial opportunities for novel agents with considerable promise, as alternative options now exist for use of tyrosine kinase inhibitors that are well tolerated and may prove worthy of regulatory approval for this disease.

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

MAPK activation as a consequence of mTORC1 inhibition is identified and the potential of a combined therapeutic approach with m TORC1 and MAPK inhibitors, currently employed as single agents in the clinic, for the treatment of human cancers is underscore.

Targeting the RET Pathway in Thyroid Cancer

Timely thyroidectomy in kindred members who have inherited a mutated RET allele, characteristic of MEN2A, MEN2B, or FMTC, can prevent MTC, the most common cause of death in these syndromes.